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Abstract: Therapeutic vaccination of patients with cancer-targeting tumor-associated
antigens is a promising strategy for the specific eradication of invasive malignancies with minimal toxicity to normal tissues. However, as increasingly potent modalities for stimulating immunologic responses are developed for clinical evaluation, the risk of inflammatory and autoimmune toxicities also may be exacerbated. In this report, we describe the induction of a severe (Grade 3) immunologic reaction in a patient with newlydiagnosed glioblastoma (GBM) receiving autologous RNA-pulsed dendritic cell (DC) vaccines admixed with GM-CSF and administered coordinately with cycles of doseintensified temozolomide (diTMZ). Shortly after the eighth administration of the admixed intradermal vaccine, the patient experienced dizziness, flushing, conjunctivitis, headache, and the outbreak of a disseminated macular/papular rash and bilateral indurated injection Introduction: Immunotherapy is an innovative approach to the treatment of invasive malignancies that holds considerable promise for the development of effective and nontoxic treatment for refractory tumors such as glioblastoma (GBM). Autologous dendritic cell (DC) vaccines are a cellular therapeutic platform that has been deployed in patients with GBM with the aim of the active induction of potent antitumor immunity that spares normal eloquent cortex (1) (2) (3) (4) . DCs pulsed with GBM tumor antigens in the form of lysates, defined peptides, or antigen-encoding RNAs, have been shown to be safe while inducing immunologic responses and promising antitumor efficacy in early stage clinical studies (5) (6) (7) (8) (9) (10) (11) . In attempts to potentiate these immune responses, adjuvants such as GM-CSF are often incorporated into vaccine formulations (12, 13) . GM-CSF is naturally produced to stimulate white blood cells, and is not expected to precipitate hypersensitivity.
Furthermore, autologous DC vaccines have rarely been reported to induce intolerable inflammatory toxicity or autoimmune reactivity in patients receiving intradermal injection of antigen-pulsed DCs. We report the induction of a severe hypersensitivity reaction in a patient with GBM enrolled on a clinical trial evaluating the use of autologous DCs pulsed with human cytomegalovirus (CMV) pp65 RNA and co-injected with recombinant GM-CSF (sargramostim) as an adjuvant. CMV antigens have been reported by several groups to be expressed in GBM tumors and we have demonstrated the relevance of CMV pp65 as an immunologic target in GBM tumors (10, (14) (15) (16) . This is our first experience of a severe immunologic reaction in a patient receiving autologous DC vaccination, which occurred despite the patient being on continuous cycles of lymphodepletive and myelosuppressive TMZ. These results demonstrate the capacity to induce significant immunologic reactions with repetitive vaccination including hypersensitivities in an immunosuppressed patient population receiving intensive chemotherapy. Clinical work up of this episode demonstrates capacity to rationally evaluate vaccine hypersensitivity in order to minimize subsequent risk in treated patients.
Case Report: This is a 55-year-old white male with newly-diagnosed GBM who underwent left parietal craniotomy resulting in gross total resection (>95% removal of enhancing lesion). One month post-resection, the patient enrolled on a clinical trial evaluating autologous RNA-pulsed DC vaccines plus GM-CSF in patients with newly-diagnosed GBM The vaccine components (GM-CSF and autologous RNA-pulsed DCs) were tested separately in small doses by skin reaction test. Administration of a test dose of GM-CSF resulted in the almost immediate development of localized induration consistent with a positive skin-test reaction. We subsequently performed skin testing using autologous RNA-pulsed DCs alone at the time of the scheduled ninth vaccine. The patient received a test dose of 0.02 mL (1 x 10 6 DCs) followed by a dose 0.08 mL (4 x 10 6 DCs) an hour later. After tolerating these test doses, he received the remainder of the vaccine (1.5 x 10 7 ; 0.3mL in three separate intradermal injection sites) one hour later. He did not develop any symptoms after receiving the DC vaccine without inclusion of GM-CSF suggesting that the allergic response was restricted to adjuvant GM-CSF. Evaluation of antibodies present in the patient's serum samples confirmed the detection of IgG, IgE, and IgM antibodies against GM-CSF.
Interestingly, the patient developed T-cell responses against pp65 after serial vaccinations that correlated with the development of anti-GM-CSF-specific antibodies; however, the T cells were not reactive to GM-CSF. To verify that he did not develop hypersensitivity against pp65, evaluation for anti-pp65 polyclonal antibodies was performed and they were unchanged over baseline at the time of the reaction. Thus, GM-CSF was implicated in precipitating the patient's hypersensitivity reaction and was removed from future vaccine preparations. The patient completed the remainder of the vaccine regimen (10 total DC vaccines) without incident. Alternatively, type II reactions involve binding of IgG and IgM to host antigens leading to lysis by complement or phagocytosis similar to that in autoimmune diseases such as rheumatoid arthritis (24) . These reactions are typically more insidious and involve end organs such as joints and kidneys (24) . This patient's skin rash and abrupt onset of symptoms appear inconsistent with a type II reaction. Type III reactions involve antigenantibody complexes leading to complement activation in serum-sickness and autoimmune illnesses such as systemic lupus erythematosus (23) . This immune complex deposition mediates endothelial damage and is often associated with fever and skin rashes (23) .
Methods and Results:

ATTAC-GM Protocol-
Through the duration of this clinical presentation, the patient remained afebrile with expeditious resolution of his symptoms, thus inconsistent with a prototypical type III reaction. Type IV reactions (delayed type hypersensitivity or DTH) involve sensitized T lymphocytes and are typically localized, occurring 48-72 hours after exposure presenting with diffuse skin erythema, induration and blister formation as in contact dermatitis (i.e. poison ivy) and tuberculin skin testing (25) . However, given the patient's abrupt symptom onset with multisystem involvement, delayed hypersensitivity to sargramostim is also inconsistent with this presentation. Additionally, other etiologies of severe immunologic reactions including a systemic cytokine release syndrome ("cytokine storm") secondary to 
